Fenofibrate Dosing with Atorvastatin
When combining fenofibrate with atorvastatin, use standard-dose fenofibrate (145-160 mg daily) without dose adjustment for the statin interaction, but reduce fenofibrate dose based on renal function: use 48-54 mg daily for eGFR 30-59 mL/min/1.73m² and avoid fenofibrate entirely if eGFR <30 mL/min/1.73m² 1.
Standard Dosing for Normal Renal Function
The FDA label data demonstrates minimal pharmacokinetic interaction between atorvastatin and fenofibrate. When atorvastatin 20 mg was co-administered with fenofibrate 160 mg for 10 days, atorvastatin levels decreased by only 17% (AUC) with no change in Cmax, while fenofibrate levels decreased by a clinically insignificant 2-4% 1. This lack of meaningful interaction is further supported by a 2015 study showing no significant pharmacokinetic drug interaction between the two agents 2.
Therefore, use fenofibrate 145-160 mg once daily with any dose of atorvastatin in patients with normal renal function.
Renal Function-Based Dose Adjustments
The critical factor determining fenofibrate dosing is renal function, not the atorvastatin dose:
Mild to Moderate Renal Impairment (eGFR 30-59 mL/min/1.73m²)
- Reduce fenofibrate to 48-54 mg once daily
- Patients show increased fenofibric acid half-life but similar overall exposure
- Monitor renal function regularly, as fenofibrate can increase serum creatinine by approximately 10% and decrease eGFR by 10% 1, 3
Severe Renal Impairment (eGFR <30 mL/min/1.73m²)
- Avoid fenofibrate entirely
- These patients show 2.7-fold increased fenofibric acid exposure with accumulation during chronic dosing 1
Practical Considerations
Monitoring requirements:
- Check baseline renal function before initiating combination therapy
- Recheck creatinine and eGFR within 2-3 months of starting fenofibrate
- In one study, 55.1% of fenofibrate patients showed creatinine increases ≥0.1 mg/dL, and 34.7% had eGFR decreases ≥10 mL/min/1.73m² 3
Muscle toxicity risk:
- The 2016 AHA guidelines note that fibrate-statin combinations increase muscle-related toxicity risk 5.5-fold compared to statin monotherapy 4
- However, fenofibrate is preferred over gemfibrozil for statin combinations because fenofibrate does not inhibit glucuronidation pathways
- Atorvastatin has minimal renal excretion (<2%), making it a safer statin choice with fenofibrate than alternatives with higher renal clearance 4
Dosing schedule:
- Both drugs can be taken once daily without regard to timing relative to each other
- Fenofibric acid has a 20-hour half-life, supporting once-daily dosing 1
- Fixed-dose combinations of atorvastatin 20 mg/fenofibrate 145-160 mg are bioequivalent to separate tablets and may improve adherence 5, 6
No atorvastatin dose adjustment needed: The atorvastatin dose should be selected based on LDL-C goals, independent of fenofibrate use. Studies have used atorvastatin doses ranging from 5-40 mg successfully with fenofibrate 160-200 mg 7, 8, 9.